GENETIX Pharmaceuticals Garners $35,000,000 Series B Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c2a3c4b2-67ad-40c6-8f8f-58d20b4be0af&Preview=1 - Date
3/12/2010 - Company Name
GENETIX Pharmaceuticals - Mailing Address
840 Memorial Drive Cambridge, MA 02139 - Company Description
GENETIX’ LentiGlobin hemoglobin gene therapy utilizes a highly modified human lentivirus to deliver a corrective version of the native beta-globin gene to the chromosomes of blood stem cells, found in large numbers in bone marrow. - Website
http://www.genetixpharm.com - Transaction Type
Venture Equity - Transaction Amount
$35,000,000 - Transaction Round
Series B - Proceeds Purposes
Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team. - M&A Terms
- Venture Investor
Third Rock Ventures - Venture Investor
Genzyme Ventures - Venture Investor
TVM Capital - Venture Investor
Forbion Capital Partners - Venture Investor
Easton Hunt Capital Partners
